Lasofoxifene

This MedLibrary.org supplementary page on Lasofoxifene is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Lasofoxifene
Systematic (IUPAC) name
(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
Identifiers
CAS number 180916-16-9
ATC code G03XC
PubChem 216416
Chemical data
Formula C28H31NO2 
Mol. mass 413.55 or 563.64 (with tartrate)
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Lasofoxifene (INN) (proposed tradename Fablyn) is a selective estrogen receptor modulator (SERM) which is under development by Pfizer Inc. for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy[1], and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND).

In September 2005, Pfizer Inc. received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.

On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is now to be marketed under the tradename Fablyn.

References

  1. ^ Gennari L, Merlotti D, Martini G, Nuti R (2006). "Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis". Expert Opin Investig Drugs 15 (9): 1091–103. doi:10.1517/13543784.15.9.1091. PMID 16916275. 

External links

v • d • e
Sex hormones and related agents (primarily G03, also L02, H01C) - human endogenous in CAPS
Progestogens:
(receptor)
Agonist
Antiprogestogen
Androgens:
(receptor)
Agonist
Estrogens:
(receptor)
Agonist
Antiestrogen
Gonadotropins:
(FSHR/LHCGR)
ovulation stim.
Antigonadotropin
GnRH:
(receptor)
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Wikipedia content modification information:

  • This page was last modified on 16 August 2008, at 00:20.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Lasofoxifene".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.